Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze IOVA Iovance Biotherapeutics, Inc.. Please read: https://finlab.finance/en/setup?stock=IOVA

No install, open FinLab Studio

IOVA

Iovance Biotherapeutics, Inc. Healthcare As of 2026-08-06 Updated daily after market close

quality needs a look, discounted valuation.

3 active signals
52-week adjusted-price high Top-quintile 6-month momentum EPS surprise beat
This page refreshes daily after the close. Add Iovance Biotherapeutics, Inc. to your watchlist to track signal changes on your next visit.
Valuation 43Quality 13Growth 64Momentum 96Risk / liquidity 46

Is Iovance Biotherapeutics, Inc. a buy? Fundamentals and valuation first

  • Quality is weaker than peers. Operating margin is only around the 11th percentile. TTM ROE is about -49.0%.

  • Valuation is cheaper than most peers. TTM P/E is in the 20th percentile, lower than most liquid US common stocks.

  • Recent volatility is elevated. 60-day annualized volatility is in the 92th percentile. Average 20-day dollar volume is about $95.6M.

  • Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum, EPS surprise beat currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

14 historical occurrences (since 2017-09-19)
Average forward return after 52-week adjusted-price high。20-day: Win 46.2%, Sample 13, Median -3.39%, Excess +4.65%, Beat mkt rate 46.2%；60-day: Win 53.8%, Sample 13, Median +1.75%, Excess +7.77%, Beat mkt rate 53.8%；120-day: Win 41.7%, Sample 12, Median -9.47%, Excess -5.34%, Beat mkt rate 41.7%

120 days after: historical avg +4.25%

20-day +4.65%
60-day +10.57%
120-day +4.25%
20-day
60-day
120-day
Win
46.2%
53.8%
41.7%
Sample
13
13
12
Median
-3.39%
+1.75%
-9.47%
Excess
+4.65%
+7.77%
-5.34%
Beat mkt rate
46.2%
53.8%
41.7%

Over 12 occurrences, 120-day forward avg gained 4.25%, lagged the market by 5.34 pts; win rate 41.7%.

Top-quintile 6-month momentum

Active · now 98.63945578231292%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

22 historical occurrences (since 2016-07-08)
Average forward return after Top-quintile 6-month momentum。20-day: Win 59.1%, Sample 22, Median +3.39%, Excess +10.26%, Beat mkt rate 54.5%；60-day: Win 61.9%, Sample 21, Median +9.95%, Excess +11.81%, Beat mkt rate 57.1%；120-day: Win 50%, Sample 20, Median +1.87%, Excess +5.72%, Beat mkt rate 45%

120 days after: historical avg +12.86%

20-day +10.39%
60-day +14.23%
120-day +12.86%
20-day
60-day
120-day
Win
59.1%
61.9%
50%
Sample
22
21
20
Median
+3.39%
+9.95%
+1.87%
Excess
+10.26%
+11.81%
+5.72%
Beat mkt rate
54.5%
57.1%
45%

Over 20 occurrences, 120-day forward avg gained 12.86%, beat the market by 5.72 pts; win rate 50%.

EPS surprise beat

Active · now 17.5783006144163%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

17 historical occurrences (since 2015-08-10)
Average forward return after EPS surprise beat。20-day: Win 53.3%, Sample 15, Median +0.58%, Excess -3.89%, Beat mkt rate 53.3%；60-day: Win 53.3%, Sample 15, Median +5.63%, Excess +2.8%, Beat mkt rate 53.3%；120-day: Win 50%, Sample 14, Median -4.06%, Excess -1.94%, Beat mkt rate 50%

120 days after: historical avg +4.91%

20-day -2.23%
60-day +6.96%
120-day +4.91%
20-day
60-day
120-day
Win
53.3%
53.3%
50%
Sample
15
15
14
Median
+0.58%
+5.63%
-4.06%
Excess
-3.89%
+2.8%
-1.94%
Beat mkt rate
53.3%
53.3%
50%

Over 14 occurrences, 120-day forward avg gained 4.91%, lagged the market by 1.94 pts; win rate 50%.

Market-wide momentum baseline

Across 98,056 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.18%, a 58.1% positive-return rate, and +2.82 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.